Lenire Now Included in U.S. ENT Clinical Practice Guidelines

Neuromod Lenire tinnitus treatment system. The American Academy of Otolaryngology-Head and Neck Surgery Foundation (AAO-HNSF) has included Lenire (bimodal neuromodulation) as a treatment option in the Academy’s new Clinical Practice Guidelines for Tinnitu s. Bimodal neuromodulation is the only new treatment recommendation added to the AAO-HNSF guidelines since their establishment in 2014....

Continue reading at Hearing Tracker →

Audiologists and ENTs managing tinnitus patients now have guideline-level backing to offer or refer for Lenire bimodal neuromodulation; clinicians should familiarise themselves with AAO-HNSF eligibility criteria and the device's recommended protocol.

Inclusion in AAO-HNSF Clinical Practice Guidelines marks a significant legitimisation of bimodal neuromodulation as a tinnitus therapy option in the U.S., potentially widening patient access and insurance coverage conversations.

1. 01AAO-HNSF updated its Clinical Practice Guidelines for Tinnitus to include Lenire as a recognised treatment option.
2. 02Lenire uses bimodal neuromodulation — pairing sound delivered via headphones with mild tongue-tip electrical stimulation.
3. 03The device is developed by Neuromod, an Irish medical technology company.
4. 04Guideline inclusion can influence clinician referral patterns and payer coverage decisions.
5. 05This is the first bimodal neuromodulation device to reach this guideline status in the U.S. for tinnitus.